The surge in demand for and media coverage surrounding glucagon-like peptide-1 receptor agonist (GLP-1RA) medications, such as semaglutide (e.g., Wegovy, Ozempic) and tirzepatide (e.g., Zepbound, Mounjaro), has prompted a growing number of individuals with obesity to consider these therapies for weight loss [1,2,3]. This evidence concerns the gene GLP1R and Obesity.